Full Text View
Tabular View
No Study Results Posted
Related Studies
Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
This study has been completed.
Study NCT00261807   Information provided by University of Maryland
First Received: December 1, 2005   Last Updated: May 30, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Fasciitis, Necrotizing
Fournier's Gangrene
Additional conditions recognized in this trial
Communicable Diseases
Fasciitis
Fournier Gangrene
Gangrene
Infection
Soft Tissue Infections
More general conditions related to this trial
Bacterial Infections
Genital Diseases, Male
Musculoskeletal Diseases
Necrosis
Pathologic Processes
Skin Diseases, Bacterial
Interventions listed in this trial
Daptomycin 6mg/kg/day
Additional drug interventions recognized in this trial
Daptomycin
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
University of Maryland
Cubist Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services